SEC Fo	orm 4																	
FORM 4				UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).							t to Section 16(a) of the In	es Exchange	_	HIP	Estim		er: verage burd sponse:	3235-0287 en 0.5				
1. Name and Address of Reporting Person [*] <u>MCHUGH THOMAS S</u>							r Name and Ticker DEL PHARN]		(Cheo	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify								
(Last) (First) (Middle) C/O AVADEL PHARMACEUTICALS PLC							of Earliest Transac 2024	ay/Year)		A below) below) Chief Financial Officer								
10 EARLSFORT TERRACE						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) DUBLI										Form filed by More than One Reporting Person								
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
			Т	able I - No	n-Deriv	ative S	ecurities Acq	uired,	, Disj	posed of,	, or Ben	eficially	Owned					
1. Title of Security (Instr. 3) 2. Trans. Date (Month/I					action Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			5. Amour Securitie Beneficia Owned F Reported	s ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
						Code V Amount (A) or (D) Pric						Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
							curities Acqui						Dwned					
1. Title of	2.		3. Transaction	3A. Deemed	I 4.		5. Number of 6	. Date E	xercis	able and	7. Title and	Amount	8. Price of	9. Numb	er of	10.	11. Natur	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	n Date Execution Date, (Month/Day/Year) Execution Date, if any Code (Instr. 8) Action (Month/Day/Year) B (Month/Day/Year) Action (Month/Day/Year) Acti		5. Number Derivativ Securitie Acquired or Dispos of (D) (In 3, 4 and 5	re s I (A) sed str.	6. Date Exerc Expiration Da (Month/Day/Y	ation Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (Right to Buy)	\$13.57	02/20/2024		A		157,500		(1)	02/20/2034	ADSs ⁽²⁾	157,500	\$0.00	157,500	D	

Explanation of Responses:

1. Options become exercisable as to 39,375 ADSs on each of the first four anniversaries after the 2/20/2024 grant date.

2. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value \$0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

/s/ Jerad G. Seurer, as Attorney-03/04/2024 in-Fact Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.